SCHEMBL2869479

SCHEMBL2869479

O=C(NC(=O)C1CNCC2C(=O)OC(c3ccccc3)(c3ccccc3)N12)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
CASP1 P29466 1/20 0.34
CASP8 Q14790 1/20 0.34
CYP1A2 P05177 1/20 0.33
GPR6 P46095 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.33
TP53 P04637 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SSTR4 P31391 1/20 0.32
GAA P10253 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA7 P36544 1/20 0.32
CHRNA4 P43681 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868059 0.85 NPSR1 (0.39) MC4RNPSR1LMNAALDH1A1NPC1
SCHEMBL2860998 0.83 NPSR1 (0.41) MC4RNPSR1LMNASSTR4
SCHEMBL2856717 0.81 NPSR1 (0.46) NPSR1LMNAMEN1MAPTKMT2A
SCHEMBL2861976 0.81 ALDH1A1 (0.40) NPSR1LMNAALDH1A1NPC1RAB9A
SCHEMBL2864536 0.81 MC4R (0.46) MC4RNPSR1ALDH1A1TP53GAA
SCHEMBL6039452 0.81 HTR4 (0.39) NPSR1CASP1CASP8ALDH1A1
Hydrochloric Acid SCHEMBL2862020 0.80 HTR4 (0.39) NPSR1CASP1CASP8ALDH1A1
SCHEMBL2861932 0.80 ALDH1A1 (0.39) NPSR1LMNAALDH1A1GAAMEN1
SCHEMBL2864826 0.80 F10 (0.40) NPSR1LMNAALDH1A1RAB9A
SCHEMBL2870723 0.80 MEN1 (0.39) NPSR1NPC1RAB9AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 MC4R 1517/4885NPSR1 211/4885CASP1 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.